BioNexus Gene Lab (BGLC) Payables (2020 - 2026)

BioNexus Gene Lab (BGLC) has 7 years of Payables data on file, last reported at $2137.0 in Q1 2026.

• For the quarter ending Q1 2026, Payables fell 91.45% year-over-year to $2137.0; the trailing twelve-month figure through Mar 2026 stood at $2137.0 (down 91.45% YoY), and the FY2025 full-year result was $2335.0, down 99.84% from the prior year.
• Payables fell to $2137.0 in Q1 2026, from $2335.0 in the prior quarter.
• In the past five years, Payables ranged from a high of $1.9 million in Q4 2022 to a low of $2137.0 in Q1 2026.
• A 5-year average of $967995.3 and a median of $1.3 million in 2022 frame the typical range for Payables.
• Across the five-year window, Payables surged 6737.65% in 2024 and plunged 99.84% in 2025, its largest moves.
• Tracing BGLC's Payables over 5 years: stood at $1.9 million in 2022, then slumped by 98.82% to $21986.0 in 2023, then surged by 6737.65% to $1.5 million in 2024, then sank by 99.84% to $2335.0 in 2025, then slipped by 8.48% to $2137.0 in 2026.
• Business Quant data shows BGLC's Payables at $2137.0 in Q1 2026, $2335.0 in Q4 2025, and $184600.0 in Q3 2025.